X-PECT Trial is Fully Enrolled

The X-PECT phase III clinical trial has finished recruiting over 430 patients, evaluating perifosine treatment for patients with advanced colorectal cancer who have exhausted standard treatments. The trial compares the effectiveness of adding perifosine to Xeloda® (capecitabine). Led by Johanna Bendell, M.D., from the Sarah Cannon Research Institute in Nashville, TN, the trial is being conducted…  Read More

CRC Groups Join Together to Offer Clinical Trial Matching

Leading colorectal cancer advocacy organizations Colon Cancer Alliance and Fight Colorectal Cancer announced that they are teaming up on an initiative to encourage patients with colorectal cancer to take charge of their diagnosis and learn about clinical trials. The Colorectal Cancer Clinical Trial Call to Action campaign matches colorectal cancer patients with currently recruiting clinical trials…  Read More

Help Answer Questions About Exercise after Colon Cancer Treatment

Are you done — or almost done — with your treatment for colon cancer? Will you help answer a question about how to help colon cancer survivors  increase their physical activity? You’ll learn more about colon cancer and may be randomly assigned to a special interactive program that is designed to help recovering colon cancer patients…  Read More

Hedgehog Fails to Help Advanced Colorectal Cancer Patients

In disappointing news, adding the Hedgehog inhibitor GDC-0449 to standard chemotherapy failed to increase the time before advanced colorectal cancer got worse. Researchers compared progression-free survival between patients who got either FOLFOX or FOLFIRI chemotherapy with Avastin and a group who got the same chemo regimen with GDC-0449. There was no difference

No Benefit Adding Cetuximab to Chemo for Stage III Colon Cancer

Adding Erbitux® (cetuximab) to standard chemotherapy for stage III colon cancer didn’t improve patient outcomes and added more side effects. All of the patients in the NO147 trial had cancer that had spread to their lymph nodes and had surgery before beginning chemotherapy. They had normal or wild-type KRAS genes in their tumors.They were randomly assigned…  Read More

Clinical Trial at NIH for Unresectable Liver Tumors

Patients with liver tumors, including those that have spread from colorectal cancer, can enroll in a clinical trial at the National Institutes of Health Clinical Center in Bethesda. The trial will test the effectiveness of infusing the drug melphalan through the artery that feeds the liver. Colorectal cancer patients with liver metastases are eligible for the…  Read More